Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | Director · CEO and President | May 27, 2022 | June 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date May 27, 2022 · Filed June 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2032-05-26 | Direct | 100,000 |
Reported balance
After 2022-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-27 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option vests in full on September 1, 2022, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on September 1, 2022, subject to the reporting person's continuous service to the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2022 Filed Jun 1, 2022 16:25 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-22-033158 · doc4.xml · derivative · entry 1 Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: The stock option vests in full on September 1, 2022, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 16:43 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 10,000 | $3.15 | $31,500.00 |
DisclosureSEC source: 0001209191-22-020791 · doc4.xml · nonDerivative · entry 1 Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,983 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 16:57 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001787297-22-000002 · primary_doc.xml · derivative · entry 1 Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 18:05 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 2,000 | $13.12 | $26,230.00 |
DisclosureSEC source: 0001209191-21-035051 · doc4.xml · nonDerivative · entry 1 Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,983 F1 · balance_after: Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:26 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 262,000 | $0.00 Strike: $21.85 | $0.00 |
DisclosureSEC source: 0001209191-21-012156 · doc4.xml · derivative · entry 2 Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 Underlying: Common Stock · 262,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 18:40 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 1,100 | $18.00 | $19,800.00 |
DisclosureSEC source: 0001209191-20-015623 · doc4.xml · nonDerivative · entry 1 Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.